Insurers balk at covering GYN treatment by OhioHealth
OhioHealth recently spent $3.5 million on equipment for a less-invasive treatment of benign but sometimes problematic tumors that grow on the uterus. And the health system has spent additional money to advertise the outpatient uterine-fibroid procedure, which was approved by the U.S. Food and Drug Administration eight years ago. OhioHealth officials said they anticipated some initial push-back from insurers to paying for the procedure, which OhioHealth had expected to perform 80 to 100 times a year by 2014. But the reluctance, they said, has been far greater than expected from health insurers such as Anthem, Aetna and Medical Mutual of Ohio.
- EHR Systems 'Immature, Costly,' AMA Says
- Anthem Blue Cross, 7 CA Health Systems Create New Challenger, Business Model
- Data Points to Boom in Private HIX
- Few Winners Among MSSP Participants
- Interstate Medical Licensure Effort Advances
- Technology Lights Up Health Innovation Forum
- How to Build a Health Plan from Scratch
- Better HCAHPS Scores Protect Revenue
- Malnourishment 'Epidemic' Plagues Hospitals? Really?
- Hospitals and doctors fail patients by passing the buck on insurance rules